These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2123 related articles for article (PubMed ID: 8044834)

  • 1. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells.
    Herr W; Wölfel T; Heike M; Meyer zum Büschenfelde KH; Knuth A
    Cancer Immunol Immunother; 1994 Aug; 39(2):93-9. PubMed ID: 8044834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
    Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
    Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
    de Vries JE; Spits H
    J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy.
    Slingluff CL; Darrow TL; Seigler HF
    Ann Surg; 1989 Aug; 210(2):194-202. PubMed ID: 2787972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K; Platsoucas CD; Balch CM
    J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells.
    Coulie PG; Somville M; Lehmann F; Hainaut P; Brasseur F; Devos R; Boon T
    Int J Cancer; 1992 Jan; 50(2):289-97. PubMed ID: 1730522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma.
    LeMay LG; Kan-Mitchell J; Goedegebuure P; Harel W; Mitchell MS
    Cancer Immunol Immunother; 1993 Aug; 37(3):187-94. PubMed ID: 8101473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells.
    Arienti F; Sulé-Suso J; Belli F; Mascheroni L; Rivoltini L; Melani C; Maio M; Cascinelli N; Colombo MP; Parmiani G
    Hum Gene Ther; 1996 Oct; 7(16):1955-63. PubMed ID: 8930655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A.
    Hayashi Y; Hoon DS; Park MS; Terasaki PI; Morton DL
    Cancer Immunol Immunother; 1992; 34(6):419-23. PubMed ID: 1373343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells.
    Berger TG; Haendle I; Schrama D; Lüftl M; Bauer N; Pedersen LØ; Schuler-Thurner B; Hohenberger W; Straten Pt Pt; Schuler G; Becker JC
    Int J Cancer; 2004 Aug; 111(2):229-37. PubMed ID: 15197776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy.
    Ellem KA; O'Rourke MG; Johnson GR; Parry G; Misko IS; Schmidt CW; Parsons PG; Burrows SR; Cross S; Fell A; Li CL; Bell JR; Dubois PJ; Moss DJ; Good MF; Kelso A; Cohen LK; Dranoff G; Mulligan RC
    Cancer Immunol Immunother; 1997 Mar; 44(1):10-20. PubMed ID: 9111579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.
    Kan-Mitchell J; Huang XQ; Steinman L; Oksenberg JR; Harel W; Parker JW; Goedegebuure PS; Darrow TL; Mitchell MS
    Cancer Immunol Immunother; 1993 Jul; 37(1):15-25. PubMed ID: 8513449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response.
    Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R
    Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene.
    Baurain JF; Colau D; van Baren N; Landry C; Martelange V; Vikkula M; Boon T; Coulie PG
    J Immunol; 2000 Jun; 164(11):6057-66. PubMed ID: 10820291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients.
    Kan-Mitchell J; Liggett PE; Harel W; Steinman L; Nitta T; Oksenberg JR; Posner MR; Mitchell MS
    Cancer Immunol Immunother; 1991; 33(5):333-40. PubMed ID: 1831067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.
    Germeau C; Ma W; Schiavetti F; Lurquin C; Henry E; Vigneron N; Brasseur F; Lethé B; De Plaen E; Velu T; Boon T; Coulie PG
    J Exp Med; 2005 Jan; 201(2):241-8. PubMed ID: 15657293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.
    Coulie PG; Karanikas V; Colau D; Lurquin C; Landry C; Marchand M; Dorval T; Brichard V; Boon T
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10290-5. PubMed ID: 11517302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
    Carrasco J; Van Pel A; Neyns B; Lethé B; Brasseur F; Renkvist N; van der Bruggen P; van Baren N; Paulus R; Thielemans K; Boon T; Godelaine D
    J Immunol; 2008 Mar; 180(5):3585-93. PubMed ID: 18292586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
    Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
    J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma.
    Anichini A; Fossati G; Parmiani G
    Int J Cancer; 1985 May; 35(5):683-9. PubMed ID: 3158614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 107.